Key result
Type 2 diabetes and metabolic syndrome in men with coronary artery disease were associated with impaired diastolic function but not with increased myocardial fibrosis, cardiomyocyte hypertrophy, or altered microvascular structure.
Why the study?
Does type 2 diabetes or metabolic syndrome alter myocardial structure and microvasculature in men with coronary artery disease?
Cross-Sectional (n=46)
Single-blind
No
Does type 2 diabetes or metabolic syndrome alter myocardial structure and microvasculature in men with coronary artery disease?
Impaired diastolic function in diabetic and metabolic syndrome patients with coronary artery disease is not dependent on increased myocardial fibrosis or cardiomyocyte hypertrophy, suggesting these structural changes may be a consequence rather than an initiating cause of cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
T2DM and MetS alter myocardial structure in RCT; extends animal/autopsy data, warrants targeted antifibrotic trials.
Campbell et al. (2011) conducted a cross-sectional in Coronary artery disease (n=46). Type 2 diabetes and metabolic syndrome vs. Control (no diabetes or metabolic syndrome) was evaluated on Myocardial interstitial fibrosis, cardiomyocyte width, and capillary length density. Type 2 diabetes and metabolic syndrome in men with coronary artery disease were associated with impaired diastolic function but not with increased myocardial fibrosis, cardiomyocyte hypertrophy, or altered microvascular structure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: